Impact BioMedical, a unit of DSS (NYSE:DSS), has disclosed terms for a proposed $8M initial public offering.
The Texas-based company said in an SEC filing that it was looking to offer 2M shares priced between $3 and $5, which would raise around $8M if priced at the midpoint.
Underwriters would receive a 45-day option to buy up to 300K additional shares to cover over-allotments. Aegis Capital is serving as bookrunner.
The company also plans on conducting a 1-for-55 reverse split ahead of the offering.
Impact Biomedical discovers, confirms and patents unique sciences and technologies in the healthcare space that can be developed with external partners.